Results 91 to 100 of about 874,057 (168)

Recent Advances in Localized Scleroderma

open access: yesSclerosis
Localized scleroderma (LSc), or morphea, is an autoimmune connective tissue disease causing inflammation and fibrosis of the skin and underlying tissues. While distinct from systemic sclerosis, its clinical presentation is highly diverse.
Toshiya Takahashi   +2 more
doaj   +1 more source

Localized scleroderma: A rare clinical entity

open access: yes, 2014
Localized Scleroderma (LS), which is also referred to as morphea, is an inflammatory disease that leads to diffuse or localized fibrotic and atrophic skin hardening.
Ravneet Arora   +2 more
core   +1 more source

Localized scleroderma: case report and literature review. [PDF]

open access: yes
Background. Localized scleroderma is a rare chronic autoimmune inflammatory disorder, belonging to the spectrum of sclerosing skin diseases, affecting patients of any age, more frequently Caucasian females.
Pargaliauskaitė, Julija,
core  

The Importance of the Skin Syndrome in the Primary Diagnosis of Connective Tissue Diseases in Children: Case Report

open access: yesПедиатрическая фармакология
Background. Timely verification of the clinical diagnosis of connective tissue diseases in children based on the onset of the earliest symptoms, including skin manifestations, and timely initiation of treatment can prevent the development of irreversible
Anastasia O. Zatolokina   +3 more
doaj   +1 more source

Scleroderma in children: An update

open access: yes, 2013
PURPOSE OF REVIEW: Scleroderma, in its localized and systemic presentation, represents the third most frequent rheumatic condition in childhood after juvenile idiopathic arthritis and systemic lupus erythematosus.
Cuffaro, Giorgio   +2 more
core   +1 more source

Articular involvement in juvenile localized scleroderma [PDF]

open access: yesMOJ Orthopedics & Rheumatology, 2018
Osminina MK, Geppe NA, Shpitonkova OV
openaire   +1 more source

Methotrexate and Mycophenolate Mofetil and Clinical Response in Juvenile Localized Scleroderma

open access: yesJAMA Dermatology
Importance Currently, there are no treatments approved by the US Food and Drug Administration for juvenile localized scleroderma (JLS), a rare disease. While methotrexate (MTX) is regularly used as a first-line therapy, emerging data from case series and applications in systemic sclerosis suggest that ...
de Rosas, Elena C.   +3 more
openaire   +2 more sources

Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience

open access: yes
Juvenile scleroderma (JS) is a group of diseases characterized byincreased skin thickness and fibrosis. It is the third-most commonrheumatic condition in childhood.
Colussi, Lara   +5 more
core   +1 more source

Spatial Transcriptomics Identifies Cellular and Molecular Characteristics of Scleroderma Skin Lesions: Pilot Study in Juvenile Scleroderma

open access: yes
Juvenile localized and systemic scleroderma are rare autoimmune diseases which cause significant disability and morbidity in children. The mechanisms driving juvenile scleroderma remain unclear, necessitating further cellular and molecular level studies.
Theresa Hutchins   +17 more
core   +1 more source

Home - About - Disclaimer - Privacy